Description
Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD). NASH is characterized by inflammation in the liver and liver cell damage, which can lead to scarring of the liver (cirrhosis). No medications have been approved specifically for NASH but there are numerous products in development. NASH Drug Pipeline and Market Overview looks at the almost 80 drug candidates for the treatment of this disease in terms of developer, type of drug, phase study, and market entrance estimate. In addition, the report provides the following data:
- Estimated Treatment Cost for NASH Therapies, Low-, Mid-, High-Range, 30-day Supply
- NASH Market Estimates by Global Region, 2025 Forecast (United States & Canada, EMEA, Latin America, Asia Pacific)
In creating its market forecast, Kalorama discusses the indicators that needed to be evaluated to create this estimate, commenting on:
- NASH Disease Incidence and Prevalence
- NAFLD Incidence and Prevalence
- Risk Factor Evaluation
- Pricing Trends
- Liver Transplant Statistics and Trends
- Expected Market Penetration
- Global Treatment Options and Emerging Therapies
NASH Drug Pipeline and Market Overview also covers the competitive outlook in the NASH treatment market, noting the activities of the current major players, which include:
- Intercept
- Genfit
- Allergan
- Madrigal
- Immuron
- Galectin
- Gilead
